Peptides, defined as polymers of less than 50 amino acids with a molecular weight of less
than 10 kDa, represent a fast-growing class of new therapeutics which has unique …

Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome
pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in …

Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

The difficult problem faced by multiple generation of practicing physicians is determining the
cause of abnormal liver function tests in cancer patients on chemotherapy. Hepatotoxicity …

Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow
microenvironment, resulting in apoptosis and inhibition of cell-cycle progression …

The use of oral anticancer drugs has increased during the last decade, because of patient
preference, lower costs, proven efficacy, lack of infusion-related inconveniences, and the …

Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug
Administration. It can bind to the amino acid residues of the 26S proteasome, thereby …

The aim of this study was to characterize population pharmacokinetics and the exposure–
neutropenia relationship with nanoparticle albumin‐bound (nab)‐paclitaxel in patients with …

Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of
all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal …